Back grey_arrow_rt.gif
 
Fatty Liver, NASH, NAFLD
 
NASH - Nonalcoholic steatohepatitis NAFLD -
nonalcoholic fatty liver disease
 
null.gif
 
 
  1. Fatty Liver in HIV - (07/18/17)
     
  2. Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease A Randomized Clinical Trial - NASH, hypertension, lipids, liver enzymes, weight loss - (10/20/17)
     
  3. Fatty Liver in HIV+ at IAS - (08/05/17)
     
  4. Fatty Liver / NASH at EASL - (07/03/17)
     
  5. IDWeek: Fatty Liver Disease in HIV: Predictors and Response to Statin Therapy - (10/11/17)
     
  6. IDWeek: Faster Fatty Liver Progression With Statin Than Placebo in SATURN HIV Trial - Mark Mascolini (10/11/17)
     
  7. EASL: Serum Cholesterol Changes Associated with NGM282 Treatment in Obese Insulin Resistant Cynomolgus Monkeys and NASH Patients are Reversed with Lipid Lowering Agents - (04/24/17)
     
  8. EASL: NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients - (04/24/17)
     
  9. EASL: Efficacy and Safety of Simtuzumab for the Treatment of NASH with Bridging Fibrosis or Cirrhosis: Results of Two Phase 2b, Dose-Ranging, Randomized, Placebo-Controlled Trials - (05/23/17)
     
  10. Fatty Liver, NAFLD, NASH Definitions - (06/29/17)
     
    ------------
     
  11. 20th Intnl Wrkshp Clin Pharm: Alteration of Hepatic OATP Activity Does Not Alter the Pharmacodynamic Effect of GS-0976, a Liver-Targeted ACC Inhibitor, on De Novo Lipogenesis - (05/26/19)
     
  12. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries - (05/24/19)
     
  13. Mediterranean/Low Carb Diet Superior in Reducing Hepatic Fat for Fatty Liver/NAFLD & Non-NAFLD too - (05/17/19)
     
  14. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis - (05/14/19)
     
  15. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication - (05/13/19)
     
  16. NAFLD in lipodystrophy - (05/10/19)
     
  17. EASL: THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders - (05/09/19)
     
  18. Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) - (05/08/19)
     
  19. EASL: NGM313, a Novel Activator of β-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (Liver Fat by MRI-PDFF), Inflammation (ALT, AST) and FibrogenicActivity (Pro-C3) in NAFLD Subjects - (05/08/19)
     
  20. EASL: Merck (Fatty Liver Disease/NASH) and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022 - (05/08/19)
     
  21. EASL: New Non-Invasive NASH/Fibrosis Biomarkers - A Comparative Study of Fibrosis Treatments using Aptamer-Based Quantitative Proteomics in a Model of Nonalcoholic Steatohepatitis Cirrhosis - (05/08/19)
     
  22. EASL: A Novel Approach to Funding HCV and HBV Treatment for all -Uzbekistan Pilot Project - (05/08/19)
     
  23. EASL: The short and long term impact of scaling up treatment for hepatitis B and C on disease burden - (05/08/19)
     
  24. EASL: A comparison of currently available direct acting antiviral HCV therapy in Canada - On the path to elimination - (05/08/19)
     
  25. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/08/19)
     
  26. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  27. EASL: Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  28. EASL: A Simple Algorithm Based on Electronic Medical Records to Identify NAFLD with Advanced Fibrosis in Patients with Type 2 Diabetes - (05/07/19)
     
  29. EASL: The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes - (05/07/19)
     
  30. EASL: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (05/07/19)
     
  31. EASL: The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD - (05/07/19)
     
  32. NAFLD in Lean Person EASL - Symposium: Recognising and managing the lean NAFLD patient - (05/01/19)
     
  33. EASL: Food, Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD) - (04/30/19)
     
  34. EASL: LIFESTYLE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - (04/30/19)
     
  35. EASL: The socio-economic burden of NASH in Europe and the United States: the GAIN study - (04/26/19)
     
  36. EASL: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases - (04/23/19)
     
  37. EASL: High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance - (04/23/19)
     
  38. EASL: EASL Wrap-up session: Metabolic and alcohol related liver disease, Fatty Liver/NASH - (04/23/19)
     
  39. EASL: Liver Disease in UK General Population: Fatty & Alcohol Liver Disease; Lack of Awareness: 4% aware; High Rate of Risk Factors: 89% - (04/23/19)
     
  40. FATTY LIVER in HIV+, alcohol, 50% have NAFLD, 27% Liver Fibrosis - The prevalence of liver fibrosis in HIV infected patients with abnormal liver function tests - (04/23/19)
     
  41. EASL: Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis - (04/22/19)
     
  42. EASL: A Combination of the ACC Inhibitor GS-0976 (firsocostat) and the Nonsteroidal FXR Agonist GS-9674 (cilofexor) Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients With Nonalcoholic Steatohepatitis - (04/22/19)
     
  43. EASL: APPLICATION OF GUIDELINES FOR FATTY LIVER IN TWO PROSPECTIVE COHORTS OF HIV+ PATIENTS: 32% have NAFLD; among those without NAFLD 18% with elevated ALT - (04/22/19)
     
  44. EASL: The Increasing Importance of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Human Immunodeficiency Virus (HIV) - (04/18/19)
     
  45. EASL: Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH - (04/13/19)
     
  46. EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
     
  47. The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease - Editorial - (04/10/19)
     
  48. Cirrhosis Causes Cognitive impairment, Poor Patient Outcomes - Despite HCV, SVR in the Presence of NAFLD, Alcoholic Fatty Liver Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis - (04/10/19)
     
  49. Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs .....Two thirds of HVs referred for treatment received treatment with 100% [13/13] achieving SVR12. - (04/10/19)
     
  50. Study Confirms Tesamorelin Significantly Reduces Liver Fat in HIV Patients With NAFLD - press announcement - (04/02/19)
     
  51. SHIVER: 1ST INTERNATIONAL WORKSHOP OF THE STEATOHEPATITIS IN HIV EMERGING RESEARCH (SHIVER) NETWORK - (03/01/19)
     
  52. Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - (02/27/19)
     
  53. Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (01/14/19)
     
  54. Merck Exercises Option for NGM Bio's Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes - (01/08/19)
     
  55. AASLD: Trends in Causes of Mortality in Liver Transplantation Recipients: Comparison Among NASH, ALD, and HCV Cohorts - (01/04/19)
     
  56. AASLD: Health care costs associated with NAFLD - a long-term follow up study - (01/04/19)
     
  57. AASLD: Economic Burden of Progression to Cirrhosis in Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States - (12/14/18)
     
  58. AASLD: Prevalence and Long-term Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) Among Elderly Individuals from the United States - (12/14/18)
     
  59. AASLD: Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease: The Impact of Alcohol Consumption and Metabolic Syndrome to Mortality - (12/14/18)
     
  60. AASLD: NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis(NASH) Results of a Phase 2 Multi-Center Dose Finding Study - (12/12/18)
     
  61. AASLD: NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study - (12/12/18)
     
  62. AASLD: NGM313, a Novel Once-Monthly Activator of bKlotho-FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Non- Alcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin-Resistant Patients with NAFLD - (12/12/18)
     
  63. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  64. AASLD: Validation of Fractional Synthesis Rate of Plasma Lumican as a Noninvasive Marker of Fibrogenesis in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  65. AASLD: The Incidence of Malignancies in Nonalcoholic Fatty Liver Disease - (12/11/18)
     
  66. AASLD: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Acetyl-CoA Carboxylase Inhibitor GS-0976, and Phenotypic Probe Substrates and Inhibitors - (12/11/18)
     
  67. AASLD: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (12/10/18)
     
  68. AASLD: Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis - (11/16/18)
     
  69. AASLD: Rising and Higher Healthcare Resource Utilization (HCRU) and Costs of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease of Increasing Severity - Results of a US Real-World Analysis - (11/16/18)
     
  70. AASLD: ASK1 Inhibition Reduces Progression of Liver Cirrhosis and Prevents Tumor Development in the BALB/c.Mdr2-/- Mouse Model of Biliary Fibrosis - (11/15/18)
     
  71. AASLD: Routinely Available Noninvasive Tests Discriminate Advanced Fibrosis Due to NASH in the Phase 3 STELLAR Trials of the ASK1 Inhibitor Selonsertib - (11/15/18)
     
  72. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (11/15/18)
     
  73. AASLD: The Nonsteroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2, Randomized, Placebo-Controlled Trial of Patients With NASH - (11/15/18)
     
  74. AASLD: The Nonsteroidal Farnesoid X Receptor Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis: A Phase 2, Randomized, Placebo-Controlled Trial - (11/15/18)
     
  75. AASLD: Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial - (11/15/18)
     
  76. AGE: More than 40% of HIV group has hepatic steatosis, regardless of age - Mark Mascolini (09/19/18)
     
  77. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  78. IAC: Two-fold higher chance of liver steatosis with HIV in big Brazilian study - Mark Mascolini (07/31/18)
     
  79. Mechanisms of NAFLD development and therapeutic strategies - (07/18/17)
     
  80. Time to step-up the fight against NAFLD - Comments from the Editors - (07/18/17)
     
  81. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database - (06/27/18)
     
  82. Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists - (06/15/18)
     
  83. EASL: The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/23/18)
     
  84. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis: A Population Pharmacokinetics and Exposure-Response Analysis - (05/22/18)
     
  85. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue, Reduces Fibrosis and PRO-C3 in a Mouse Model of Non-Alcoholic Steatohepatitis - (05/22/18)
     
  86. Evaluation of SOMAscan® as a Discovery Platform to Identify Noninvasive
    Protein Biomarkers for Diagnosis and Monitoring of NASH
    - (05/21/18)
     
  87. The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/21/18)
     
  88. EASL: ACC Inhibitor Demonstrates Potent Antifibrotic Activity In Vitro and In Vivo - (05/17/18)
     
  89. EASL: Responsiveness of Controlled Attenuation Parameter and Its Correlation With Magnetic Resonance Imaging-Proton Density Fat Fraction in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (05/15/18)
     
  90. EASL: Combination of an FXR Agonist and an ACC Inhibitor Increases Antifibrotic Efficacy in Rodent Models of NASH - (05/15/18)
     
  91. EASL: Preliminary Efficacy and Safety of Acetyl-CoA Carboxylase Inhibitor GS-0976 in Patients With Compensated Cirrhosis Due To NASH - (05/15/18)
     
  92. EASL: Accurate Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH Using a Bayesian Machine Learning Approach - (05/15/18)
     
  93. EASL: The Conundrum of Cryptogenic Liver Disease [NASH] with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options - (05/15/18)
     
  94. EASL: Novel Characterization of the Gut Microbiome in Patients With NASH and Longitudinal Changes Associated With Histologic Improvement - (05/15/18)
     
  95. EASL: Mechanism for Hypertriglyceridemia and Effect of Fibrate Coadministration During Acetyl-CoA Carboxylase Inhibitor Treatment - (05/11/18)
     
  96. EASL: Characterization of Changes in Lipoprotein Profiles of Patients With Nonalcoholic Steatohepatitis Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976 - (05/09/18)
     
  97. EASL: An Integrated Safety Analysis of Phase 2 Studies of BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis - (04/25/18)
     
  98. EASL: Low-moderate alcohol use is associated with a lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) - (04/24/18)
     
  99. EASL: Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI - (04/24/18)
     
  100. EASL: Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/24/18)
     
  101. EASL: Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): A large German claims database study - (04/23/18)
     
  102. EASL: NGM282 Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - (04/20/18)
     
  103. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/19/18)
     
  104. EASL: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (04/19/18)
     
  105. EASL: NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks - (04/19/18)
     
  106. EASL: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH) - (04/19/18)
     
  107. EASL: MGL-3196, a selective thyroid hormone receptor-beta agonist, significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study - (04/19/18)
     
  108. EASL: Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2b CENTAUR Study - (04/19/18)
     
  109. EASL: Proof-of-concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor (FXR) agonist (GS-9674) in NASH - (04/18/18)
     
  110. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/18/18)
     
  111. NASH Future Therapies at Paris Hepatitis Conference Jan 2018 - (02/05/18)
     
  112. Merck NASH - (01/30/18)
     
  113. Fatty Liver, NASH in HIV - (01/30/18)
     
  114. Long Term Outcomes: Mortality and Causes of Death in NAFLD - (01/30/18)
     
  115. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus - (01/08/18)
     
  116. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention - (01/08/18)
     
  117. Fatty liver disease: turning the tide - (01/08/18)
     
  118. Nonalcoholic fatty liver disease.....liver enzymes-ALT/HIV/diet, exercise, metabolic syndrome, waist circumfrance, dysfunctional adipose tissue, diabetes, screening - (01/08/18)
     
  119. Fatty Liver, NASH - Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis - (01/02/17)
     
  120. Pharmacotherapy for NASH: Current and emerging - (01/02/17)
     
  121. Determinants of fibrosis progression and regression in NASH - (01/02/17)
     
  122. NAFLD: The evolving landscape - Editorial - (01/02/17)
     
  123. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  124. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  125. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  126. NAFLD AASLD Guidelines - The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases - (12/22/17)
     
  127. NAFLD and cancer: More cause for concern? - (12/21/17)
     
  128. Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD) / HIV & the Liver, Fatty Liver/NALFD - (12/20/17)
     
  129. The Global Epidemiology of Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis - (12/19/17)
     
  130. Burden of Illness Economic Model for Patients with Non-alcoholic Steatohepatitis (NASH) in the United States - (12/19/17)
     
  131. AASLD: Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease - (12/15/17)
     
  132. PPIs Increase NASH Risk - Microbiome & Fatty Liver: gut barrier dysfunction reported by speaker, leads to increased microbes into gut going to liver, increasing inflammation, and fatty liver - (12/11/17)
     
  133. HEP DART presentations 3 -7 Dec 2017 - (12/12/17)
     
  134. HEP-DART presentations 3 Dec - 7, 2017 - (12/11/17)
     
  135. NASH Globally - Pathways to combination therapies, biomarkers and outcomes - (12/11/17)
     
  136. Unmet needs in understanding pathogenesis and management of NAFLD and NASH - (12/11/17)
     
  137. AASLD: Cardiovascular risk in NAFLD- not an equal opportunity: implications for women's health - (11/29/17)
     
  138. Cirrhosis Predicts Bad Outcomes in NASH - (07/08/17)
     
  139. Cutting out the liver fat [NASH - better animal models needed] - Editorial - (07/08/17)
     
  140. EACS: How many HIV mono-infected or HBV or HCV co-infected patients with undetectable viremia should be monitored for liver disease severity in the presence of suspect NAFLD? - (12/08/17)
     
  141. EACS: Non-viral Liver Disease Burden in HIV Mono-infected Individuals: A Prospective Cohort Study - (12/07/17)
     
  142. AASLD: Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts early NASH and disease activity - (11/29/17)
     
  143. AASLD: NAFLD Debrief AASLD 2017 - (11/29/17)
     
  144. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/29/17)
     
  145. AASLD: 4D Dynamic FDG-PET correlates with hepatic inflammation and steatosis in patients with non-alcoholic steatohepatitis - (11/29/17)
     
  146. AASLD: Multi-Biomarker Validation of MRI-PDFF- and MRE-Derived Treatment Response with BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  147. AASLD: Baseline Serum Pro-C3 Predicts Response to BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  148. AASLD: Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 "FIB-C3 Score" for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort - (11/20/17)
     
  149. AASLD: Prevalence and Clinical Characteristics of Nonalcoholic Fatty Liver Disease in Lean Subjects in Comparison with Overweight or Obese Individuals: A cross-sectional study - (11/20/17)
     
  150. AASLD: Advanced machine learning techniques to identify a panel of biomarkers that identify non-alcoholic steatohepatitis - (11/20/17)
     
  151. AASLD: Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test - (11/20/17)
     
  152. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/20/17)
     
  153. AASLD: CM-101 a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model - (11/20/17)
     
  154. AASLD: Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis - (11/20/17)
     
  155. AASLD: The Long-Term Clinical Course of Histologically Advanced NAFLD. Impact of Fibrosis Severity on Major Clinical Outcomes. - An International and Multicenter Cohort Study - (11/17/17)
     
  156. AASLD: Natural History of Nonalcoholic Fatty Liver Disease in Children - (11/17/17)
     
  157. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (10/28/17)
     
  158. AASLD: BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study - (10/26/17)
     
  159. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  160. AASLD: Identification of Circulating MicroRNAs Altered by an Apoptosis Signal-Regulating Kinase 1 Inhibitor in a Fast-food Diet NAFLD Mouse Model - (11/14/17)
     
  161. AASLD: Plasma Metabolites for de Novo Lipogenesis and Pharmacodynamic Activity of Acetyl-CoA Carboxylase Inhibitor GS-0976 - (11/14/17)
     
  162. AASLD: Variability in Measurement of Hepatic Venous Pressure Gradient in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis: Results From a Randomized, Controlled Trial - (11/14/17)
     
  163. AASLD: Hepatic Venous Pressure Gradient Predicts Clinical Disease Progression in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (11/14/17)
     
  164. AASLD: Hepatic de Novo Lipogenesis Is Elevated in Patients With NASH Across the Spectrum of Disease Severity - (11/14/17)
     
  165. AASLD: Reductions in Hepatic Proton Density Fat Fraction Predict Histologic Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  166. AASLD: Reductions in Liver Stiffness by Magnetic Resonance Elastography Predict Fibrosis Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  167. AASLD: Serum Pro-C3 Is Associated With Hepatic Steatosis and Fibrosis, and Responsive to Changes in Steatosis in Patients With NASH - (11/13/17)
     
  168. AASLD: Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/13/17)
     
  169. AASLD: Prospective Validation of Hepatic Collagen Content for the Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH - (11/13/17)
     
  170. AASLD: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) - (11/13/17)
     
  171. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (11/13/17)
     
  172. AASLD: Combination of ASK1 and ACC Inhibitors Increases Efficacy in Rodent Models of NASH - (11/13/17)
     
  173. AASLD: Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamic Effects on de Novo Lipogenesis of the Acetyl-CoA Carboxylase Inhibitor GS-0976 in Healthy Volunteers - (11/13/17)
     
  174. AASLD: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function, and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH - (11/13/17)
     
  175. AASLD: norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study - (11/13/17)
     
  176. AASLD: Racial and Ethnic Disparities in Non-Alcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Meta-Analysis - (11/13/17)
     
  177. AASLD: Performance of liver stiffness by FibroScan in a Large Prospective Multicenter UK Study: Applicability, reliability, diagnostic performance and influence of the probe type and of steatosis on the liver stiffness measurement - (11/13/17)
     
  178. NASH: Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study - New trends on obesity and NAFLD in Asia / Lean-NASH - (10/03/17)
     
  179. Treatment of NAFLD with diet, physical activity and exercise - (09/26/17)
     
  180. EASL: Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/08/17)
     
  181. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter - (09/05/17)
     
  182. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD - (09/05/17)
     
  183. IAS: Fatty Liver in HIV+ at IAS - (08/05/17)
     
  184. Current and Future Therapeutic Approaches to NAFLD/NASH - (08/05/17)
     
  185. IAS: Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17)
     
  186. Bristol-Myers NASH drug hits primary endpoint in phase 2 - (07/22/17)
     
  187. Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial - (07/22/17)
     
  188. EASL: A NEW NON-INVASIVE DIAGNOSTIC SCORE TO MONITOR CHANGE IN DISEASE ACTIVITY AND PREDICT FIBROSIS EVOLUTION IN PATIENT WITH NASH - (07/17/17)
     
  189. EASL: Prospective Prevalence Study of Adult NAFLD/NASH Utilizing Multi-Modality Imaging Compared with Liver Biopsy - (07/17/17)
     
  190. EASL: Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies - (07/17/17)
     
  191. EASL: Simple non-invasive fibrosis scores identify patients with NAFLD who progress to advanced fibrosis/cirrhosis: evidence from a large cohort of patients with sequential liver biopsies. - (07/17/17)
     
  192. EASL: DNA Methylation Signatures in Blood Show Accelerated Epigenetic Aging in Patients with Nonalcoholic Steatohepatitis Compared to Healthy Controls - (07/07/17)
     
  193. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease - (07/07/17)
     
  194. EASL: Changes in Fibrosis, But Not the NAFLD Activity Score, Are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (07/06/17)
     
  195. EASL: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial - (07/05/17)
     
  196. EASL: INT 747 (obeticholic acid) fails to achieve goals in Japanese study for non-alcoholic steatohepatitis (NASH)- Intercept Pharma + Sumitomo - (07/05/17)
     
  197. EASL: Starting the battle to control non-alcoholic steatohepatitis [OCA FLINT Study] - Comment - (07/05/17)
     
  198. EASL: Nonalcoholic Steatohepatitis Drug Pipeline Overview - (07/05/17)
     
  199. EASL: Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis - (07/05/17)
     
  200. EASL: Elafibranor - (GFT505) NASH Treatment - GOLDEN 505 Study & Commentary - (07/05/17)
     
  201. EASL: Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes - (07/05/17)
     
  202. EASL: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Farnesoid X Receptor Agonist GS-9674, and Phenotypic Probe Substrates and Inhibitors/Inducers - (07/03/17)
     
  203. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  204. EASL: Emerging Treatments for ASH & NASH - Rohit Loomba, MD / AASLD 2016 - (07/03/17)
     
  205. EASL: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Reduces Hepatic Steatosis and Liver Injury in a Murine Model of NASH - (07/03/17)
     
  206. EASL: Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multicenter Nonalcoholic Steatohepatitis Clinical Trial - (07/03/17)
     
  207. EASL: Apoptosis Signal-Regulating Kinase 1 Inhibition Reduces Liver Fibrosis and Apoptosis in an NLRP3 Mutant Model of NASH - (07/03/17)
     
  208. EASL: Impact of Weight Reduction on Serum Markers and Liver Histology Including Progression to Cirrhosis in Patients With Nonalcoholic Steatohepatitis and Bridging Fibrosis - (07/03/17)
     
  209. EASL: Impact of Modest Weight Reduction on Liver Histology, Portal Pressure, and Clinical Events in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (07/03/17)
     
  210. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  211. Fatty Liver in HIV+ / HIV Research Politics, Aging - Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy - (07/03/17)
     
  212. IWCADRH: Clinical Implications of Nonalcoholic Fatty Liver Disease in Patients with HIV Infection - (06/23/17)